James A Reiffel1, Atul Verma2, Peter R Kowey3, Jonathan L Halperin4, Bernard J Gersh5, Rolf Wachter6, Erika Pouliot7, Paul D Ziegler7. 1. Columbia University College of Physicians and Surgeons, New York, New York. 2. Southlake Regional Health Centre, Newmarket, Ontario, Canada. 3. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. 4. Mount Sinai Medical Center, New York, New York. 5. Mayo Clinic College of Medicine, Rochester, Minnesota. 6. Clinic for Cardiology and Pneumology, University Medicine Göttingen, Göttingen, Germany. 7. Medtronic, Minneapolis, Minnesota.
Abstract
Importance: In approximately 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF. Objective: To quantify the incidence of AF in patients at high risk for but without previously known AF using an insertable cardiac monitor. Design, Setting, and Participants: This prospective, single-arm, multicenter study was conducted from November 2012 to January 2017. Visits took place at 57 centers in the United States and Europe. Patients with a CHADS2 score of 3 or greater (or 2 with at least 1 additional risk factor) were enrolled. Approximately 90% had nonspecific symptoms potentially compatible with AF, such as fatigue, dyspnea, and/or palpitations. Exposures: Patients underwent monitoring with an insertable cardiac monitor for 18 to 30 months. Main Outcomes and Measures: The primary end point was adjudicated AF lasting 6 or more minutes and was assessed at 18 months. Other analyses included detection rates at points from 30 days to 30 months and among CHADS2 score subgroups. Median time from insertion to detection and the percentage of patients subsequently prescribed oral anticoagulation therapy was also determined. Results: A total of 446 patients were enrolled; 233 (52.2%) were male, and the mean (SD) age was 71.5 (9.9) years. A total of 385 patients (86.3%) received an insertable cardiac monitor, met the primary analysis cohort definition, and were observed for a mean (SD) period of 22.5 (7.7) months. The detection rate of AF lasting 6 or more minutes at 18 months was 29.3%. Detection rates at 30 days and 6, 12, 24, and 30 months were 6.2%, 20.4%, 27.1%, 33.6%, and 40.0%, respectively. At 18 months, AF incidence was similar among patients with CHADS2 scores of 2 (24.7%; 95% CI, 17.3-31.4), 3 (32.7%; 95% CI, 23.8-40.7), and 4 or greater (31.7%; 95% CI, 22.0-40.3) (P = .23). Median (interquartile) time from device insertion to first AF episode detection was 123 (41-330) days. Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (56.3%). Conclusions and Relevance: The incidence of previously undiagnosed AF may be substantial in patients with risk factors for AF and stroke. Atrial fibrillation would have gone undetected in most patients had monitoring been limited to 30 days. Further trials regarding the value of detecting subclinical AF and of prophylactic therapies are warranted. Trial Registration: clinicaltrials.gov Identifier: NCT01727297.
Importance: In approximately 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF. Objective: To quantify the incidence of AF in patients at high risk for but without previously known AF using an insertable cardiac monitor. Design, Setting, and Participants: This prospective, single-arm, multicenter study was conducted from November 2012 to January 2017. Visits took place at 57 centers in the United States and Europe. Patients with a CHADS2 score of 3 or greater (or 2 with at least 1 additional risk factor) were enrolled. Approximately 90% had nonspecific symptoms potentially compatible with AF, such as fatigue, dyspnea, and/or palpitations. Exposures: Patients underwent monitoring with an insertable cardiac monitor for 18 to 30 months. Main Outcomes and Measures: The primary end point was adjudicated AF lasting 6 or more minutes and was assessed at 18 months. Other analyses included detection rates at points from 30 days to 30 months and among CHADS2 score subgroups. Median time from insertion to detection and the percentage of patients subsequently prescribed oral anticoagulation therapy was also determined. Results: A total of 446 patients were enrolled; 233 (52.2%) were male, and the mean (SD) age was 71.5 (9.9) years. A total of 385 patients (86.3%) received an insertable cardiac monitor, met the primary analysis cohort definition, and were observed for a mean (SD) period of 22.5 (7.7) months. The detection rate of AF lasting 6 or more minutes at 18 months was 29.3%. Detection rates at 30 days and 6, 12, 24, and 30 months were 6.2%, 20.4%, 27.1%, 33.6%, and 40.0%, respectively. At 18 months, AF incidence was similar among patients with CHADS2 scores of 2 (24.7%; 95% CI, 17.3-31.4), 3 (32.7%; 95% CI, 23.8-40.7), and 4 or greater (31.7%; 95% CI, 22.0-40.3) (P = .23). Median (interquartile) time from device insertion to first AF episode detection was 123 (41-330) days. Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (56.3%). Conclusions and Relevance: The incidence of previously undiagnosed AF may be substantial in patients with risk factors for AF and stroke. Atrial fibrillation would have gone undetected in most patients had monitoring been limited to 30 days. Further trials regarding the value of detecting subclinical AF and of prophylactic therapies are warranted. Trial Registration: clinicaltrials.gov Identifier: NCT01727297.
Authors: Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sandeep R Das; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Carmen R Isasi; Monik C Jiménez; Suzanne E Judd; Brett M Kissela; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David J Magid; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Wayne Rosamond; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Daniel Woo; Robert W Yeh; Melanie B Turner Journal: Circulation Date: 2016-01-26 Impact factor: 29.690
Authors: Javed M Nasir; William Pomeroy; Adam Marler; Matthew Hann; Tina Baykaner; Ronald Jones; Richard Stoll; Katherine Hursey; Angela Meadows; Jennifer Walker; Steve Kindsvater Journal: Heart Rhythm Date: 2017-05-12 Impact factor: 6.343
Authors: Greg C Flaker; Kathy Belew; Karen Beckman; Humberto Vidaillet; Jack Kron; Robert Safford; Mary Mickel; Patrick Barrell Journal: Am Heart J Date: 2005-04 Impact factor: 4.749
Authors: James Reiffel; Atul Verma; Jonathan L Halperin; Bernard Gersh; Selcuk Tombul; John Carrithers; Lou Sherfesee; Peter Kowey Journal: Am Heart J Date: 2013-10-23 Impact factor: 4.749
Authors: Alessandro Capucci; Massimo Santini; Luigi Padeletti; Michele Gulizia; GianLuca Botto; Giuseppe Boriani; Renato Ricci; Stefano Favale; Francesco Zolezzi; Natale Di Belardino; Giulio Molon; Fabrizio Drago; Giovanni Q Villani; Elena Mazzini; Marco Vimercati; Andrea Grammatico Journal: J Am Coll Cardiol Date: 2005-10-24 Impact factor: 24.094
Authors: Giovanni L Botto; Luigi Padeletti; Massimo Santini; Alessandro Capucci; Michele Gulizia; Francesco Zolezzi; Stefano Favale; Giulio Molon; Renato Ricci; Mauro Biffi; Giovanni Russo; Marco Vimercati; Giorgio Corbucci; Giuseppe Boriani Journal: J Cardiovasc Electrophysiol Date: 2008-10-30
Authors: Carsten W Israel; Gerian Grönefeld; Joachim R Ehrlich; Yi-Gang Li; Stefan H Hohnloser Journal: J Am Coll Cardiol Date: 2004-01-07 Impact factor: 24.094
Authors: Paulus Kirchhof; Günter Breithardt; Etienne Aliot; Sana Al Khatib; Stavros Apostolakis; Angelo Auricchio; Christophe Bailleul; Jeroen Bax; Gerlinde Benninger; Carina Blomstrom-Lundqvist; Lucas Boersma; Giuseppe Boriani; Axel Brandes; Helen Brown; Martina Brueckmann; Hugh Calkins; Barbara Casadei; Andreas Clemens; Harry Crijns; Roland Derwand; Dobromir Dobrev; Michael Ezekowitz; Thomas Fetsch; Andrea Gerth; Anne Gillis; Michele Gulizia; Guido Hack; Laurent Haegeli; Stephane Hatem; Karl Georg Häusler; Hein Heidbüchel; Jessica Hernandez-Brichis; Pierre Jais; Lukas Kappenberger; Joseph Kautzner; Steven Kim; Karl-Heinz Kuck; Deirdre Lane; Angelika Leute; Thorsten Lewalter; Ralf Meyer; Lluis Mont; Gregory Moses; Markus Mueller; Felix Münzel; Michael Näbauer; Jens Cosedis Nielsen; Michael Oeff; Ali Oto; Burkert Pieske; Ron Pisters; Tatjana Potpara; Lars Rasmussen; Ursula Ravens; James Reiffel; Isabelle Richard-Lordereau; Herbert Schäfer; Ulrich Schotten; Wim Stegink; Kenneth Stein; Gerhard Steinbeck; Lukasz Szumowski; Luigi Tavazzi; Sakis Themistoclakis; Karen Thomitzek; Isabelle C Van Gelder; Berndt von Stritzky; Alphons Vincent; David Werring; Stephan Willems; Gregory Y H Lip; A John Camm Journal: Europace Date: 2013-08-27 Impact factor: 5.214
Authors: Sana M Al-Khatib; Emelia J Benjamin; Alfred E Buxton; Hugh Calkins; Mina K Chung; Anne B Curtis; Patrice Desvigne-Nickens; Pierre Jais; Douglas L Packer; Jonathan P Piccini; Yves Rosenberg; Andrea M Russo; Paul J Wang; Lawton S Cooper; Alan S Go Journal: Circulation Date: 2019-11-20 Impact factor: 29.690
Authors: William F McIntyre; Pablo A Mendoza; Emilie P Belley-Côté; Richard P Whitlock; Kevin J Um; Natalie Maystrenko; P J Devereaux; David Conen; Jorge A Wong; Stuart J Connolly; Jeff S Healey Journal: Clin Cardiol Date: 2018-10-18 Impact factor: 2.882
Authors: Geoffrey H Tison; José M Sanchez; Brandon Ballinger; Avesh Singh; Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Emily S Lee; Shannon M Fan; Rachel A Gladstone; Carlos Mikell; Nimit Sohoni; Johnson Hsieh; Gregory M Marcus Journal: JAMA Cardiol Date: 2018-05-01 Impact factor: 14.676
Authors: Vincenzo Russo; Anna Rago; Vincenzo Tavoletta; Valter Bianchi; Cristina Carella; Giuseppe Ammirati; Aniello Viggiano; Stefano De Vivo; Antonio Rapacciuolo; Gerardo Nigro; Antonio D'Onofrio Journal: J Atr Fibrillation Date: 2018-08-31
Authors: Madalena D Costa; Susan Redline; Elsayed Z Soliman; Ary L Goldberger; Susan R Heckbert Journal: Am J Physiol Heart Circ Physiol Date: 2020-09-28 Impact factor: 4.733